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1. Introduction  
Atherosclerotic cardiovascular disease (CVD) is a significant cause of morbidity and 
mortality in patients with chronic kidney disease (CKD), particularly patients undergoing 
hemodialysis (HD). The death rate from CVD in patients with advanced stage CKD is 10 to 
40 times higher than that in the general population (Iliou et al., 2001; Sarnak et al., 2003). A 
majority of patients with CKD have traditional CVD risk factors such as old age, diabetes 
mellitus, systolic hypertension, smoking, and dyslipidemia. However, the interventions to 
address these traditional risk factors have failed to decrease the risk for CVD in patients 
with CKD (Stenvinkel et al., 2008).  
Atherosclerotic lesions develop through chronic inflammatory processes, and chronic 
inflammation is a common feature of CKD. In addition, the metabolic milieu during the 
development of renal dysfunction appears to accelerate the atherosclerotic process by 
decades in patients with CKD. Given these findings, many researchers have emphasized 
that nontraditional risk factors such as oxidative stress and advanced glycation endproducts 
(AGEs), in combination with their receptor (RAGE), may play an important role in the 
development of CVD in patients with CKD. 
RAGE is a member of the immunoglobulin superfamily of cell surface molecules. Enhanced 
RAGE expression has been observed in peripheral blood monocytes of patients with CKD, 
suggesting that RAGE may amplify ligand-induced monocyte perturbation and contribute 
to monocyte-mediated vascular inflammation in patients with CKD. The major alteration of 
glycated protein in patients with CKD is decreased clearance of glycation-free adducts and 
their markedly increased levels in plasma. However, the change of plasma AGEs into 
proteins in patients with CKD is relatively modest. Therefore, ligands other than AGEs for 
RAGE may be more important in RAGE-mediated atherosclerosis of patients with CKD. 
Several RAGE ligands, including S100 proteins, the High Mobility Group Box proteins, and 
amyloid fibrils, have been identified. Among them, emerging evidence indicates that 
S100A12 is a proinflammatory cytokine (Pietzsch and Hoppmann, 2009). In this review, we 
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focus on chronic inflammation, which causes atherosclerosis in patients with CKD, and 
highlight the role of the S100A12 protein, which is upregulated in patients with CKD. 
2. CKD: An inflammatory state  
The inflammatory response is not only a local process but can also be reflected systemically 
as it is accompanied by increases in inflammatory markers including acute phase proteins, 
cytokines, and adhesion molecules. In recent years, some of these markers, such as C-
reactive protein (CRP), interleukin (IL-6), serum amyloid type A, tumor necrosis factor 
(TNF)-ǂ, adhesion molecule, and CD40 ligands, have been evaluated for their prognostic 
value in normal patients as well as in patients with CVD. Numerous studies have reported 
an association between renal impairment and different mediators and markers of 
inflammation including CRP, IL-6, and TNF-ǂ, even among patients with moderate renal 
impairment, suggesting that CKD is a low-grade inflammatory process (Landray et al., 2004; 
Stenvinkel, 2006) and peripheral polymorphonuclear leukocytes and CD14+/Cd16+ 
monocytes are key mediators in the process (Merino et al., 2008; Sela et al., 2005). 
Approximately 30–50% of predialysis, HD, and peritoneal dialysis (PD) patients have 
serological evidence of an activated inflammatory response (Stenvinkel, 2001). Serum CRP 
levels are particularly high when renal function declines to the level of end stage of renal 
disease. Elevated serum CRP is a strong predictor of cardiovascular mortality in patients 
undergoing HD (Ma et al., 1992). Thus, it is possible that inflammation could promote both 
atherosclerosis and cardiovascular mortality. However, the precise mechanisms that 
contribute to the high prevalence of inflammation in patients with CKD are not well 
understood.  
3. S100A12 protein 
Human S100 proteins are the largest subgroup within the superfamily of EF-hand calcium-
binding proteins. Currently, S100 proteins comprise a family of at least 25 low molecular 
weight proteins (9–14 kDa) (Santamaria-Kisiel et al., 2006). S100 proteins are characterized 
by the presence of two calcium-binding EF-hand motifs and display unique properties. It is 
thought that S100 proteins serve as a calcium trigger or sensor proteins that regulate the 
function and/or subcellular distribution of certain target proteins and peptides upon 
calcium-dependent activation. All S100 proteins, with the exception of S100G (calbindin D, 9 
k), are organized as tight symmetric, antiparallel homodimers (some as heterodimers), and 
the noncovalent interface between the two monomers is formed mostly by hydrophobic 
amino acid residues. Each monomer is composed of a C-terminal, classic EF-hand, common 
to all EF-hand proteins, and an N-terminal, pseudo EF-hand, which has been found 
exclusively in the N-termini of S100 and S100-like proteins (Pietzsch and Hoppmann, 2009; 
Zhou et al., 2006).  
In recent years, a subgroup of the S100 family (S100A12, S100A8, and S100A9) has been 
associated with acute/chronic inflammatory disorders (Foell et al., 2004a; Foell et al., 2004b). 
Human S100A12 was first described by Guignard and colleagues as a cytosolic protein, p6, 
in neutrophilic granulocytes and monocytes/macrophages that crossreacts with antibodies 
raised against S100A8 (Guignard et al., 1995). RAGE is of significant importance as a neutral 
target of S100A12 (Donato, 2007; Hofmann et al., 1999). Engagement of RAGE by S100A12 
activates nuclear factor (NF)-κB, a central transcription factor involved in inflammatory 
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events that triggers the expression of multiple gene products contributing to the 
inflammatory response (Hofmann et al., 1999; Yang et al., 2001). 
3.1 Gene and protein structure 
The cytogenetic location of S100A12 is part of the tight S100 gene cluster on human 
chromosome 1q21. The S100A12 gene has been mapped to 1q21.2-1q22(1q21.3) and is 
located between the S100A8 and S100A9 genes (Ravasi et al., 2004). The S100A12 gene has a 
length of approximately 4.1 kbp and consists of three exons, which are divided by two 
introns of 900 and 400 bp. Exon 2 contains part of the 5′-untranslated region (UTR) and exon 
3 contains the 3′-UTR. The mRNA size, exclusive of the polyadenylate stretch, is 466 Bp (Acc 
No. NM_005621).  
The protein is encoded by sequences in exons 2 (138 nucleotides) and 3 (138 nucleotides), 
with the two EF hand motifs of the protein separately encoded by exons 2 and 3 (Acc Nos. 
X98289, X98290, D83657) (Wicki et al., 1996; Yamamura et al., 1996) and a 276-bp open 
reading frame encoding a 92-amino acid polypeptide with a predicted molecular mass of 
10,575 Da. Homologous proteins have also been found in other species such as bovine, 
porcine, and rabbit. Human S100A12 has 70% sequence identity with both porcine and 
rabbit S100A12, and 66% sequence identity with the bovine protein (Dell'Angelica et al., 
1994; Hitomi et al., 1996; Nonato et al., 1997; Yang et al., 1996). Human S100A12 shares 40% 
identity with human S100A8 (calgranulin A; myeloid-related protein 8), and 46% identity 
with human S100A9 (calgranulin B; myeloid-related protein 14), respectively. The S100A12 
gene is not observed in rodents. The crystal structure of calcium-bound S100A12 closely 
resembles structures of other members of the calgranulin subfamily, presenting as an anti-
parallel homodimer of four-helix subunits (Moroz et al., 2003). At low molecular calcium 
concentrations, human S100A12 also forms a hexamer consisting of three symmetrically 
positioned calcium-bound homodimers (Moroz et al., 2003). Most of the S100 proteins have 
been shown in various conformational and functional states depending on the intracellular 
or extracellular concentrations of calcium, zinc, and copper. In both EF-hands, the calcium 
ion is coordinated in a pentagonal bipyramidal configuration. Generally, the dimeric S100 
proteins binds four calcium ions per dimer [~10-4 to 10-5 M (overall Kd)], with high affinity 
binding [~10-5 to 10-7 M (Kd)] at the C-terminal canonical EF-hand motifs and low affinity 
binding [~10-3 to 10-4 M (Kd)] at the N-terminal pseudo EF-hand motifs, respectively. An 
additional bound calcium ion per subunit occurs in the human S100A12 hexamer structure, 
in addition to the two calcium ions in the EF-hands. S100A12 also binds zinc ions at a 
binding site formed by both subunits that is closely located at the dimer interface. Of 
importance, divalent copper ions may bind at the same site. Coordination of both zinc and 
copper ions is supported by the N-terminal residues His15 and Asp25 from one subunit and 
two appropriately positioned imidazoles of a His-Tyr-His-Thr-His motif comprising 
residues 85–89 in the C-terminus from the other subunit (Moroz et al., 2003). These cations 
may regulate both intracellular and extracellular functions of S100A12. Studies on S100A12 
monomers isolated from porcine granulocytes demonstrate substantial regulation of 
S100A12 calcium-binding affinity by zinc (Dell'Angelica et al., 1994). Upon copper binding, 
human S100A12 dimers form close contacts possibly enabling changes in their target 
binding sites or forming oligomers (Moroz et al., 2003). However, the particular role of 
S100A12 in zinc and copper binding in normal and disease states in vivo remains to be 
elucidated.  
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3.2 Expression, secretion and regulation 
S100 lacks a signal peptide for secretion via the Golgi-mediated pathway and some debate 
exists regarding whether the high levels derived from inflammatory lesions are due to active 
secretion or passive release as a consequence of neutrophil necrosis. S100A8/9 release 
correlates with loss of neutrophil viability (Voganatsi et al., 2001), suggesting that necrosis 
probably represents a significant extracellular source of S100. In contrast, protein kinase C 
activation by pro-inflammatory stimuli, [Ca2+]I elevation by contact with activated 
endothelium (Frosch et al., 2000), and lipopolysaccharides from several bacterial species 
(Kido et al., 2005) cause a rapid release from neutrophils. S100A12 is constitutively 
expressed in neutrophils at low levels (~5% of cytosolic protein) (Guignard et al., 1995) and 
is expressed in myeloid cell lines (Vogl et al., 2004). We previously examined the amounts of 
S100A12 mRNA in cultured human THP-1 macrophages after treatment with various 
stimuli known to modulate atherosclerosis. First, IL-6, a proinflammatory cytokine, 
increased the level of S100A12 mRNA by ~2-fold in a time- and a dose-dependent fashion. 
The S100A12 protein was also detected in the culture medium and increased significantly 
after adding IL-6. Induction was abolished by pretreatment with a JAK kinase inhibitor and 
cycloheximide but not with an MEK kinase inhibitor. Second, pioglitazone, a 
thiazolidinedione, decreased the level of S100A12 mRNA by ~25% of basal in a time- and 
dose-dependent fashion. Pioglitazone also inhibited the induction of S100A12 mRNA by IL-
6. These results indicate that S100A12 production is induced by IL-6 through de novo 
protein synthesis via the JAK-STAT kinase pathway and inhibited by activation of the 
peroxisome proliferator-activated receptor-Ǆ (PPAR-Ǆ) in human macrophages (Hasegawa 
et al., 2003). Ligand-bound PPAR-Ǆ represses signal-dependent transcription of many 
inflammatory proteins (Pascual and Glass, 2006). The rapid upregulation by pro-
inflammatory stimuli and repression by PPAR-Ǆ agonists is consistent with the pro-
inflammatory role of S100A12 (Goyette and Geczy, 2010). Nevertheless, further studies are 
needed to clarify the S100A12 regulatory mechanism.  
3.3 Binding partners and function 
Despite the large interest in the (patho-)physiological properties of human S100A12, 
knowledge of its intracellular targets is still limited. In bovine S100A12, annexin 5, aldolase, 
cytosolic NADP+-dependent isocitrate dehydrogenase, and glyceraldehyde-3-phosphate 
dehydrogenase show either a strict or weak calcium-dependent interaction with S100A12 
(Hatakeyama et al., 2004).  
The best known extracellular target protein is RAGE (Donato, 2007). RAGE is the first cell 
surface receptor that binds specifically to several members of the S100 protein family, 
including S100A12, S100A1, S100B, and S100P (Arumugam et al., 2004; Dattilo et al., 2007; 
Donato, 2007; Hofmann et al., 1999). The binding of S100 proteins, including calgranulins 
S100A6 and S100A18, is still debated (Goyette and Geczy, 2010). Engagement of the 
extracellular domain of the RAGE membrane by calcium-bound S100A12 activates 
intracellular signal cascades, including MAP kinase and NF-κB, which induce cytokine 
secretion (e.g., TNF-ǂ and IL-1ǃ), and expression of adhesion molecules (e.g., ICAM-1 and 
VCAM-1), and thereby mediate their pro-inflammatory effects on lymphocytes, endothelial 
cells, neutrophils, and mononuclear phagocytes (Yang et al., 2001), leading to the development 
of several chronic inflammation such as asthmatic lung (Yang et al., 2007), rheumatoid 
synovuim (Yang et al., 2001), inflamed mucosa in inflammatory bowel disease (Leach et al., 
2007), diabetes mellitus (Kosaki et al., 2004), and atherosclerosis (Mori et al., 2009). 
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3.4 Association of plasma S100A12 level with atherosclerotic CVD in CKD 
In 2009, we were the first to report that plasma S100A12 levels in 72 patients undergoing HD 
had mean levels 2.3-fold higher than those in control subjects. Furthermore, maximum carotid 
artery intima-media thickness correlated positively with plasma S100A12 levels in patients 
with HD, suggesting that plasma S100A12 levels are associated with atherosclerosis as a 
complication of CKD in patients undergoing HD (Mori et al., 2009). We also found that plasma 
S100A12 levels were elevated in patients undergoing PD (~2-fold), and in a high group of the 
peritoneal equilibrium test, suggesting the influence of chronic inflammation (Uchiyama-
Tanaka et al., 2007). Consequently, a larger cross-sectional dataset of 550 patients undergoing 
HD at our affiliated hospital was analyzed to assess the relationship between plasma S100A12 
levels and the presence of CVD (Shiotsu et al., 2011). We found that plasma S100A12 levels in 
patients undergoing HD with a history of CVD were significantly higher than those in patients 
with no history of CVD. Furthermore, plasma S100A12 level was identified as an independent 
factor associated with the prevalence of CVD, and higher plasma S100A12 levels were 
associated with an increased risk for CVD. These results suggest that plasma S100A12 protein 
may be a novel predictor of CVD events in patients undergoing HD. This finding was 
compatible with a report by another group (Nakashima et al., 2011) that conducted a 
prospective study including 184 patients undergoing prevalent HD. Plasma concentrations of 
S100A12 and sRAGE were studied in relation to risk profile and mortality after a median 
follow-up period of 41 months. The results showed that S100A12 and sRAGE levels were 
significantly elevated in patients undergoing HD compared with those in healthy controls. 
S100A12 had a strong positive correlation with CRP and IL-6, whereas sRAGE was negatively 
associated with CRP. S100A12, but not sRAGE, was independently and positively associated 
with clinical CVD. Further adjustment for inflammation made the predictive value of S100A12 
disappear for all-cause mortality, but it still persisted for CVD-related mortality. In another 
population, the expression of RAGE and S100A12 in peripheral blood mononuclear cells 
(PBMCs) of subjects with pre-mature coronary artery disease (CAD) for the first time without 
CKD and diabetes were reported (Mahajan et al., 2009). Semi-quantitative RT-PCR was 
performed to determine RAGE and S100A12 transcriptional expression in PBMCs. Increased 
expression of RAGE and EN-RAGE in non-diabetic patients with pre-mature CAD was 
observed, suggesting a significant contribution of enhanced S100A12 expression in PBMCs to 
CAD pathophysiology. 
4. Conclusion 
Circulating S100A12 is elevated in patients with CKD and is associated with CVD events 
and CVD-related mortality, which is partly explained by its links to inflammation. Further 
studies are apparently needed from a therapeutic point of view. It is likely that a 
modification in uremic state affects S100A12 expression in neutrophils and/or monocytes. 
The identification of “activated” leucocytes and interventions by targeted therapy for such a 
leucocyte population may be beneficial to prevent CVD in patients with CKD. 
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